Fundraising FoxQCDx LLC
Farmington, US · Founded 2016 · Connecticut LLC · 1 known investors
Find your way into QCDx LLC
Each arrow is one introduction. Sign up to fill in the first one.
19 people can intro you to Triantafyllos
Ask Hassan Bennani to introduce you to Triantafyllos Tafas Ph.D.
You →Hassan · together at Ikonisys →Triantafyllos
Sign up to find every way you can get introduced to QCDx LLC
- Your email: who you already know at QCDx LLC, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the QCDx LLC team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
QCDx develops liquid biopsy technologies using live 3D imaging to detect and profile circulating tumor cells for cancer diagnosis and drug development. The RareScope platform enables oncologists to optimize treatment strategies and therapeutic agents through single-cell phenotypic analysis of rare cancer cells in early-stage and advanced disease.
Founders & leadership
QCDx LLC was founded in 2016 by Triantafyllos Tafas and Triantafyllos Tafas Ph.D..
TT
Triantafyllos TafasFounder & CEOTriantafyllos Tafas founded QCDx in 2017 to develop liquid biopsy technologies for cancer diagnosis. He previously co-founded Ikonisys in 2000, where he served as Chief Technology Officer and President, and developed Down Syndrome screening technology that was acquired by Chromavision; he holds a B.S. in biology and Ph.D. in evolution and populations biology from the University of Athens.
TT
Triantafyllos Tafas Ph.D.Founder & CEOTafas holds a Ph.D. in evolution and population biology from the University of Athens and founded QCDx in 2017 to develop liquid biopsy technologies for cancer diagnostics. Previously, he co-founded Ikonisys in 2000, serving as Chief Technology Officer and President, and developed prenatal chromosomal abnormality screening technology that was acquired by Chromavision.
Investors · 1
Reported raises · per SEC filings
Form D private placements$130K disclosed across 1 round · 2017
▶$130KraisedJan 2018 · 3 investors · Other TechnologyRule 506(b)
▶$130KraisedJan 2018 · 3 investors · Other Technology
Rule 506(b)Officers, directors & promoters on the filing
- Triantafyllos TafasExecutive Officer, Director, Promoter
- Offering amount
- $225K
- Amount sold
- $130K
- First sale
- Dec 2017
- Incorporated
- Limited Liability Company, Connecticut, 2016
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 8
CdxdiagnosticsCDx Diagnostics develops AI-powered diagnostic technology that detects precancerous cells in the gastrointestinal tract to enable early cancer prevention. The proprietary platform combines computer imaging, artificial intelligence, and molecular biology for healthcare providers.
CareDxCareDx provides innovative solutions and diagnostic tools for transplant patients throughout their pre- and post-transplant journey to improve outcomes and equity in organ transplantation.
LabcorpLabCorp provides diagnostic testing services and clinical trial recruitment solutions that connect patient insights to drug development for healthcare providers.
IQVIAIQVIA is a healthcare data and technology company that supports life sciences organizations in research, clinical development, and commercialization of medicines and medical solutions.
MDxHealthMDxHealth is a commercial-stage precision diagnostics company offering molecular diagnostic tests to guide the diagnosis and treatment of prostate cancer and other urologic diseases. Its tests use proprietary genetic, epigenetic, and molecular technologies and serve physicians, patients, payers, and providers.
Quest DiagnosticsQuest Diagnostics is the world's leading provider of diagnostic information services, serving one in three adult Americans and half of US physicians and hospitals. The company offers diagnostic insights and testing services to consumers and healthcare providers to support health decision-making.
AgilentAgilent manufactures laboratory instruments, software, reagents, and consumables for pharmaceutical, diagnostics, clinical research, and applied markets including chemicals, food, and environmental sectors. The company operates through three segments: Life Sciences and Diagnostics Markets (which includes contract manufacturing services for oligonucleotide therapeutics and pathology solutions), Agilent CrossLab (providing lab services and automation), and Applied Markets (offering analytical instruments and software).
GenedxGeneDx provides advanced genetic testing and clinical interpretation services to help clinicians diagnose rare and inherited genetic disorders, with AI-driven genomic intelligence that supports patient care decisions and accelerates research and drug discovery.
Companies working in the same space as QCDx LLC.
Frequently asked questions
- What does QCDx LLC do?
- QCDx develops liquid biopsy technologies using live 3D imaging to detect and profile circulating tumor cells for cancer diagnosis and drug development. The RareScope platform enables oncologists to optimize treatment strategies and therapeutic agents through single-cell phenotypic analysis of rare cancer cells in early-stage and advanced disease.
- Who founded QCDx LLC?
- QCDx LLC was founded by Triantafyllos Tafas, Triantafyllos Tafas Ph.D. in 2016.
- Who are QCDx LLC's investors?
- QCDx LLC's investors include Connecticut Innovations.
- How much funding has QCDx LLC raised?
- QCDx LLC has disclosed $130K raised across 1 round.
- Where is QCDx LLC headquartered?
- QCDx LLC is headquartered in Farmington, US.